West Pharmaceutical Services (WST) — insider trading
Health Care · NYSE
West Pharmaceutical Services (WST) has 54 reported SEC Form 4 insider transactions in our data, including 8 open-market sales among the most recent 54 (latest 2026-09-30).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | HAUGEN JANET BRUTSCHEA | Director | Grant / award / vesting (derivative) | 44 | $370.76 | $16.3K | Form 4 |
| 2026-09-15 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion (derivative) | 2,524 | — | $0 | Form 4 |
| 2026-09-15 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Open-market sale | 2,524 | $365.00 | $921.3K | Form 4 |
| 2026-09-15 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion | 2,524 | $89.64 | $226.3K | Form 4 |
| 2026-09-14 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion (derivative) | 2,500 | — | $0 | Form 4 |
| 2026-09-14 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Open-market sale | 2,500 | $355.00 | $887.5K | Form 4 |
| 2026-09-14 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion | 2,500 | $89.64 | $224.1K | Form 4 |
| 2026-09-11 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion (derivative) | 2,500 | — | $0 | Form 4 |
| 2026-09-11 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Open-market sale | 2,500 | $345.00 | $862.5K | Form 4 |
| 2026-09-11 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion | 2,500 | $89.64 | $224.1K | Form 4 |
| 2026-09-08 | Lagarde Michel | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 3,600 | — | $0 | Form 4 |
| 2026-09-08 | Lagarde Michel | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 4,950 | — | $0 | Form 4 |
| 2026-09-08 | Lagarde Michel | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 6,200 | — | $0 | Form 4 |
| 2026-09-08 | Lagarde Michel | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 12,088 | — | $0 | Form 4 |
| 2026-09-08 | Lagarde Michel | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 11,081 | — | $0 | Form 4 |
| 2026-09-08 | Lagarde Michel | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 13,879 | — | $0 | Form 4 |
| 2026-09-08 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion (derivative) | 2,500 | — | $0 | Form 4 |
| 2026-09-08 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion (derivative) | 2,818 | — | $0 | Form 4 |
| 2026-09-08 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion (derivative) | 2,817 | — | $0 | Form 4 |
| 2026-09-08 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Open-market sale | 2,500 | $340.81 | $852.0K | Form 4 |
| 2026-09-08 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion | 2,500 | $89.64 | $224.1K | Form 4 |
| 2026-09-08 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Open-market sale | 2,818 | $340.81 | $960.4K | Form 4 |
| 2026-09-08 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion | 2,818 | $83.47 | $235.2K | Form 4 |
| 2026-09-08 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Open-market sale | 2,817 | $340.81 | $960.1K | Form 4 |
| 2026-09-08 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion | 2,817 | $83.47 | $235.1K | Form 4 |
| 2026-08-11 | McMahon Robert W. | Officer (SVP & Chief Financial Officer) | Option exercise / conversion (derivative) | 794 | — | $0 | Form 4 |
| 2026-08-11 | McMahon Robert W. | Officer (SVP & Chief Financial Officer) | Option exercise / conversion (derivative) | 6,355 | — | $0 | Form 4 |
| 2026-08-11 | McMahon Robert W. | Officer (SVP & Chief Financial Officer) | Shares withheld for taxes / exercise cost | 2,764 | $351.37 | $971.1K | Form 4 |
| 2026-08-11 | McMahon Robert W. | Officer (SVP & Chief Financial Officer) | Option exercise / conversion | 6,355 | — | — | Form 4 |
| 2026-08-11 | McMahon Robert W. | Officer (SVP & Chief Financial Officer) | Shares withheld for taxes / exercise cost | 346 | $351.37 | $121.4K | Form 4 |
| 2026-08-11 | McMahon Robert W. | Officer (SVP & Chief Financial Officer) | Option exercise / conversion | 794 | — | — | Form 4 |
| 2026-06-30 | HAUGEN JANET BRUTSCHEA | Director | Grant / award / vesting (derivative) | 46 | $359.00 | $16.5K | Form 4 |
| 2026-05-12 | Campbell Shane Alden | Officer (SVP, Proprietary Segment) | Option exercise / conversion (derivative) | 474 | — | $0 | Form 4 |
| 2026-05-12 | Campbell Shane Alden | Officer (SVP, Proprietary Segment) | Option exercise / conversion (derivative) | 296 | — | $0 | Form 4 |
| 2026-05-12 | Campbell Shane Alden | Officer (SVP, Proprietary Segment) | Shares withheld for taxes / exercise cost | 135 | $312.07 | $42.1K | Form 4 |
| 2026-05-12 | Campbell Shane Alden | Officer (SVP, Proprietary Segment) | Option exercise / conversion | 474 | — | — | Form 4 |
| 2026-05-12 | Campbell Shane Alden | Officer (SVP, Proprietary Segment) | Shares withheld for taxes / exercise cost | 84 | $312.07 | $26.3K | Form 4 |
| 2026-05-12 | Campbell Shane Alden | Officer (SVP, Proprietary Segment) | Option exercise / conversion | 296 | — | — | Form 4 |
| 2026-05-04 | BUTHMAN MARK A | Director | Grant / award / vesting | 791 | — | $0 | Form 4 |
| 2026-05-04 | Feehery William F | Director | Grant / award / vesting | 791 | — | $0 | Form 4 |
| 2026-05-04 | FRIEL ROBERT F | Director | Grant / award / vesting | 791 | — | $0 | Form 4 |
| 2026-05-04 | HAUGEN JANET BRUTSCHEA | Director | Grant / award / vesting | 791 | — | $0 | Form 4 |
| 2026-05-04 | Joseph Molly | Director | Grant / award / vesting | 791 | — | $0 | Form 4 |
| 2026-05-04 | Keller Deborah L | Director | Grant / award / vesting | 791 | — | $0 | Form 4 |
| 2026-05-04 | LAI GOLDMAN MYLA | Director | Grant / award / vesting | 791 | — | $0 | Form 4 |
| 2026-05-04 | Lockhart Stephen H | Director | Grant / award / vesting | 791 | — | $0 | Form 4 |
| 2026-05-04 | Michels Douglas A | Director | Grant / award / vesting | 791 | — | $0 | Form 4 |
| 2026-05-04 | Pucci Paolo | Director | Grant / award / vesting | 791 | — | $0 | Form 4 |
| 2026-04-27 | Winters Chad | Officer (VP, Chief Accounting Officer) | Option exercise / conversion (derivative) | 896 | — | $0 | Form 4 |
| 2026-04-27 | Winters Chad | Officer (VP, Chief Accounting Officer) | Open-market sale | 896 | $300.67 | $269.4K | Form 4 |
| 2026-04-27 | Winters Chad | Officer (VP, Chief Accounting Officer) | Option exercise / conversion | 896 | $173.22 | $155.2K | Form 4 |
| 2026-04-27 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion (derivative) | 2,817 | — | $0 | Form 4 |
| 2026-04-27 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Open-market sale | 2,817 | $305.20 | $859.8K | Form 4 |
| 2026-04-27 | Favorite Annette F | Officer (Sr. VP & Chief HR Officer) | Option exercise / conversion | 2,817 | $83.47 | $235.1K | Form 4 |
Ask the chat about WST's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: West Pharmaceutical Services (WST).
Last updated 2026-09-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.